Published :
Tables : 200
Figures : 83
Category : Healthcare
No. of Pages : 220
Report Code : HC-1282
In Vitro Diagnostic Market Introduction: In-Vitro Diagnostics Market is estimated to value over USD 91.6 billion by 2027 end and register a CAGR of over 4.8% during the forecast period 2020 to 2027. Technological advancements in in-vitro diagnostic techniques have contributed to the global in-vitro diagnostics market growth. With the assistance of key players in launching advanced in-vitro diagnostic tools, the market for these products will most likely see much growth. For instance, Qiagen, which is a company that ranks as one of the prominent providers of point of care molecular diagnostics, provides the highest record of accurate results for particularized patient treatments. Moreover, the government officiated the healthcare system and other organizations have had a positive effect on market growth. Owing to government programs, there has been significant education and information regarding IVD tools and personalized medication and treatment. All these factors have served as the basis for lucrative business opportunities. Thus, the exorbitant costs of in-vitro treatment may pose potential problems in the progress during the forecast time frame. The market is expected to see a boost in the demand for in-vitro diagnostic kits and reagents. Major players are looking to develop highly innovative kits for an accurate diagnosis. There is a demand for software in diagnostic devices and tools by medical professionals. Also, there has also been a need for it in terms of diagnosing various chronic diseases. By technology, the market has been divided into applications related to clinical chemistry. This clinical chemistry includes diagnosing blood glucose levels and detection of hormone fluctuations. Application-wise, alarming levels of ailments in cardiovascular diseases include stroke, arrhythmia and coronary artery disease is expected to spurn the demand for in-vitro diagnostic treatments. Based on the end-user, point of care diagnostic examinations includes pregnancy kits, glucose meters and biosensors that will deliver fast results. Observing the segmentation by region, North America and the Asia Pacific have been predicted to hold the largest global in-vitro diagnostics market share. A rise in diseases, as well as growing awareness in the public arena, has propelled much considerable growth in the region of North America. In the Asia Pacific region, shifts in healthcare reforms and healthcare expenditure is registered to boost regional business growth. While the market for in-vitro consists of many major players, there are smaller to midsize companies as well who are making their presence felt in the market by adopting technological changes and improvements in their products. These strategies are carried out by launching products at a much lower price. Some of these companies include Siemens Healthcare, Abbott Laboratories, Qiagen N.V., Thermo Fischer Scientific Inc., F. Hoffmann-La Roche AG, Roche Diagnostics, Danaher Corporation, Sysmex Corporation, Becton, Dickinson and Company, Biomérieux Sa, Bio-Rad Laboratories, Inc., Johnson & Johnson, Agilent Technologies, Qiagen, Diasorin, Leica Biosystems Nussloch GmbH, Cepheid have acquired a sizeable market share. Impact of COVID-19 on In vitro Diagnostics Market: The FDA has announced policies for developing specific laboratories that can conduct diagnostic tests for COVID-19. FDA has published some guidelines that are intended to aid the United States in increasing the capacity of rapid testing. Furthermore, the agency emphasized that they are not updating or changing their standards in order to issue an Emergency Use Authorization (EUA). Currently the in vitro diagnostic tests for diagnosing COVID-19 are based on real time RT-PCR testing. It is a nuclear-derived procedure that detects the presence of a genetic material from a virus. The method uses fluorescent dyes, replacing the isotope labelling which helps the scientists in obtaining immediate results even while the process is ongoing. Companies like Abbott Laboratories, Thermo Fisher Scientific, Quidel Corp., Roche Diagnostics and Hologic have receives EUA license from FDA for the commercialization of diagnostic assays used for COVID-19. Such factors can aid in the augmentation of the market. In vitro Diagnostics Market Segmentation: By Product and Services Reagents & Kits Instruments Data Management Software Services By Technology Immunochemistry/Immunoassay Clinical Chemistry Molecular Diagnostics Microbiology Hematology Coagulation & Hemostasis Urinalysis Others By Application Diabetes Infectious Diseases Oncology/Cancer Cardiology Nephrology Autoimmune Diseases Drug Testing/Pharmacogenomics HIV/AIDS Others By End User Laboratories Hospitals Academics Point-Of-Care Testing Patient Self-Testing Others By Region North America Europe Asia Pacific Latin America Middle East & Africa FutureWise Key Takeaways: Growth prospects SWOT analysis Key trends Key data-points affecting market growth Objectives of the Study: To provide with an exhaustive analysis on the In-vitro diagnostics market by product & services, by technology, by application, by end user and by region To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) To evaluate and forecast micro-markets and the overall market To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East & Africa To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions Profiling of companies to evaluate their market shares, strategies, financials and core competencies Flexible Delivery Model: We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement The customization Mobility Care offered are free of charge with purchase of any license of the report You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
In-Vitro Diagnostics Market is estimated to value over USD 91.6 billion by 2027 end and register a CAGR of over 4.8% during the forecast period 2020 to 2027. Technological advancements in in-vitro diagnostic techniques have contributed to the global in-vitro diagnostics market growth. With the assistance of key players in launching advanced in-vitro diagnostic tools, the market for these products will most likely see much growth. For instance, Qiagen, which is a company that ranks as one of the prominent providers of point of care molecular diagnostics, provides the highest record of accurate results for particularized patient treatments. Moreover, the government officiated the healthcare system and other organizations have had a positive effect on market growth. Owing to government programs, there has been significant education and information regarding IVD tools and personalized medication and treatment. All these factors have served as the basis for lucrative business opportunities. Thus, the exorbitant costs of in-vitro treatment may pose potential problems in the progress during the forecast time frame. The market is expected to see a boost in the demand for in-vitro diagnostic kits and reagents. Major players are looking to develop highly innovative kits for an accurate diagnosis. There is a demand for software in diagnostic devices and tools by medical professionals. Also, there has also been a need for it in terms of diagnosing various chronic diseases. By technology, the market has been divided into applications related to clinical chemistry. This clinical chemistry includes diagnosing blood glucose levels and detection of hormone fluctuations. Application-wise, alarming levels of ailments in cardiovascular diseases include stroke, arrhythmia and coronary artery disease is expected to spurn the demand for in-vitro diagnostic treatments. Based on the end-user, point of care diagnostic examinations includes pregnancy kits, glucose meters and biosensors that will deliver fast results. Observing the segmentation by region, North America and the Asia Pacific have been predicted to hold the largest global in-vitro diagnostics market share. A rise in diseases, as well as growing awareness in the public arena, has propelled much considerable growth in the region of North America. In the Asia Pacific region, shifts in healthcare reforms and healthcare expenditure is registered to boost regional business growth. While the market for in-vitro consists of many major players, there are smaller to midsize companies as well who are making their presence felt in the market by adopting technological changes and improvements in their products. These strategies are carried out by launching products at a much lower price. Some of these companies include Siemens Healthcare, Abbott Laboratories, Qiagen N.V., Thermo Fischer Scientific Inc., F. Hoffmann-La Roche AG, Roche Diagnostics, Danaher Corporation, Sysmex Corporation, Becton, Dickinson and Company, Biomérieux Sa, Bio-Rad Laboratories, Inc., Johnson & Johnson, Agilent Technologies, Qiagen, Diasorin, Leica Biosystems Nussloch GmbH, Cepheid have acquired a sizeable market share.
Impact of COVID-19 on In vitro Diagnostics Market:
The FDA has announced policies for developing specific laboratories that can conduct diagnostic tests for COVID-19. FDA has published some guidelines that are intended to aid the United States in increasing the capacity of rapid testing. Furthermore, the agency emphasized that they are not updating or changing their standards in order to issue an Emergency Use Authorization (EUA). Currently the in vitro diagnostic tests for diagnosing COVID-19 are based on real time RT-PCR testing. It is a nuclear-derived procedure that detects the presence of a genetic material from a virus. The method uses fluorescent dyes, replacing the isotope labelling which helps the scientists in obtaining immediate results even while the process is ongoing. Companies like Abbott Laboratories, Thermo Fisher Scientific, Quidel Corp., Roche Diagnostics and Hologic have receives EUA license from FDA for the commercialization of diagnostic assays used for COVID-19. Such factors can aid in the augmentation of the market.
In vitro Diagnostics Market Segmentation:
By Product and Services
By Technology
By Application
By End User
By Region
FutureWise Key Takeaways:
Objectives of the Study:
Flexible Delivery Model:
1. Market Introduction 1.1 Objectives of the Study 1.2 Market Definition 1.3 Market Scope 1.3.1 Years Considered for the Study 1.3.2 Market Covered 1.4 Currency 1.5 Limitations 1.6 Stakeholders 2. Research Methodology 2.1 Research Data 2.1.1 Secondary Data 2.1.1.1 Key Data From Secondary Sources 2.1.2 Primary Data 2.2.2.1 Key Data From Primary Sources 2.2 Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4 Assumptions for the Study 3. Executive Summary 3.1 Market Outlook 3.2 Segment Outlook 3.3 Competitive Insights 4. Global In Vitro Diagnostics Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards And Compliances 5. Global In Vitro Diagnostics Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of In Vitro Diagnostics Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Global In Vitro Diagnostics Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Global In Vitro Diagnostics Market, By Product and Services Historical Analysis and Forecast 2020-2027 (USD Million) 7.1. Reagents & Kits 7.2. Instruments 7.2.1. Fully-automated Instruments 7.2.2. Semi-automated Instruments 7.2.3. Others 7.3. Data Management Software 7.4. Services 7.5. Extremities Implant 8. Global In Vitro Diagnostics Market, By Technology Historical Analysis and Forecast 2020-2027 (USD Million) 8.1. Immunochemistry/Immunoassay 8.1.1. Enzyme-Linked Immunosorbent Assay (ELISA) 8.1.1.1. Chemiluminescence Immunoassay (CLIA) 8.1.1.2. Fluorescence Immunoassay (FIA) 8.1.1.3. Colorimetric Immunoassay (CI) 8.1.2. Radioimmunoassays (RIA) 8.1.3. Rapid Tests 8.1.4. Western Blot 8.1.5. ELISPOT 8.2. Clinical Chemistry 8.2.1. Basic Metabolic Panel 8.2.2. Electrolyte Panel 8.2.3. Liver Panel 8.2.4. Lipid Profile 8.2.5. Renal Profile 8.2.6. Thyroid Function Panel 8.2.7. Specialty Chemicals 8.3. Molecular Diagnostics 8.3.1. Polymerase Chain Reaction (PCR) 8.3.2. Isothermal Nucleic Acid Amplification Technology (INAAT) 8.3.3. Hybridization (In-situ Hybridization & FISH) 8.3.4. DNA Sequencing & NGS 8.3.5. Microarray 8.3.6. Others 8.4. Microbiology 8.5. Hematology 8.6. Coagulation & Hemostasis 8.7. Urinalysis 8.8. Others 9. Global In Vitro Diagnostics Market, By Application Historical Analysis and Forecast 2020-2027 (USD Million) 9.1. Diabetes 9.2. Infectious Diseases 9.3. Oncology/Cancer 9.4. Cardiology 9.5. Nephrology 9.6. Autoimmune Diseases 9.7. Drug Testing/Pharmacogenomics 9.8. HIV/AIDS 9.9. Others 10. Global In Vitro Diagnostics Market, By End User Historical Analysis and Forecast 2020-2027 (USD Million) 10.1. Laboratories 10.1.1. Large/Reference Laboratories 10.1.2. Medium-sized Laboratories 10.1.3. Small Laboratories 10.2. Hospitals 10.3. Academics 10.4. Point-Of-Care Testing 10.5. Patient Self-Testing 10.6. Others 11. North America In Vitro Diagnostics Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 11.2.1. U.S.A 11.2.2. Canada 11.3. Market Size (USD Million) Forecast for North America 2020-2027 12. Latin America In Vitro Diagnostics Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 12.2.1. Brazil 12.2.2. Mexico 12.2.3. Rest of Latin America 12.3. Market Size (USD Million) Forecast for Latin America 2020-2027 13. Europe In Vitro Diagnostics Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 13.2.1. Germany 13.2.2. U.K 13.2.3. France 13.2.4. Italy 13.2.5. Spain 13.2.6. Russia 13.2.7. Poland 13.2.8. Rest of Europe 13.3. Market Size (USD Million) Forecast for Europe 2020-2027 14. Asia Pacific In Vitro Diagnostics Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 14.2.1. Japan 14.2.2. China 14.2.3. India 14.2.4. Australia and New Zealand 14.2.5. ASEAN 14.2.6. Rest of Asia Pacific 14.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027 15. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Connected Devices and Disease Indication Portfolio, Financial Layouts) 15.1. Roche Diagnostics 15.1.1. Company Overview 15.1.2. Product Portfolio 15.1.3. SWOT Analysis 15.1.4. Financial Overview 15.1.5. Strategic Overview 15.2. Danaher Corporation 15.2.1. Company Overview 15.2.2. Product Portfolio 15.2.3. SWOT Analysis 15.2.4. Financial Overview 15.2.5. Strategic Overview 15.3. Abbott Laboratories, Inc. 15.3.1. Company Overview 15.3.2. Product Portfolio 15.3.3. SWOT Analysis 15.3.4. Financial Overview 15.3.5. Strategic Overview 15.4. Siemens AG 15.4.1. Company Overview 15.4.2. Product Portfolio 15.4.3. SWOT Analysis 15.4.4. Financial Overview 15.4.5. Strategic Overview 15.5 Sysmex Corporation 15.5.1. Company Overview 15.5.2. Product Portfolio 15.5.3. SWOT Analysis 15.5.4. Financial Overview 15.5.5. Strategic Overview 15.6 Thermo Fisher Scientific 15.6.1. Company Overview 15.6.2. Product Portfolio 15.6.3. SWOT Analysis 15.6.4. Financial Overview 15.6.5. Strategic Overview 15.7. Becton, Dickinson and Company 15.7.1. Company Overview 15.7.2. Product Portfolio 15.7.3. SWOT Analysis 15.7.4. Financial Overview 15.7.5. Strategic Overview 15.8. Biomérieux Sa 15.8.1. Company Overview 15.8.2. Product Portfolio 15.8.3. SWOT Analysis 15.8.4. Financial Overview 15.8.5. Strategic Overview 15.9. Bio-Rad Laboratories, Inc. 15.9.1. Company Overview 15.9.2. Product Portfolio 15.9.3. SWOT Analysis 15.9.4. Financial Overview 15.9.5. Strategic Overview 15.10. Johnson & Johnson 15.10.1. Company Overview 15.10.2. Product Portfolio 15.10.3. SWOT Analysis 15.10.4. Financial Overview 15.10.5. Strategic Overview 15.11. Agilent Technologies 15.11.1. Company Overview 15.11.2. Product Portfolio 15.11.3. SWOT Analysis 15.11.4. Financial Overview 15.11.5. Strategic Overview 15.12. Qiagen 15.12.1. Company Overview 15.12.2. Product Portfolio 15.12.3. SWOT Analysis 15.12.4. Financial Overview 15.12.5. Strategic Overview 15.13. Diasorin 15.13.1. Company Overview 15.13.2. Product Portfolio 15.13.3. SWOT Analysis 15.13.4. Financial Overview 15.13.5. Strategic Overview 15.14. Leica Biosystems Nussloch GmbH 15.14.1. Company Overview 15.14.2. Product Portfolio 15.14.3. SWOT Analysis 15.14.4. Financial Overview 15.14.5. Strategic Overview 15.15. Cepheid 15.15.1. Company Overview 15.15.2. Product Portfolio 15.15.3. SWOT Analysis 15.15.4. Financial Overview 15.15.5. Strategic Overview 16. Impact of COVID-19 16.1. Positive influence on the healthcare industry 16.2. The financial disruption of the manufacturing sector 16.3. Impact of COVID-19 on emerging companies 16.4. Significant mandates in the healthcare regulations initiated by administrations 16.5. The overall economic slowdown of the developing and developed nations 17. FutureWise SME Key Takeaway Points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics